Literature DB >> 6695817

Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds.

K J Hellestrand, A W Nathan, R S Bexton, A J Camm.   

Abstract

The acute electrophysiologic effects of i.v. flecainide acetate (2 mg/kg body weight) were assessed in 71 patients undergoing electrophysiologic study. Ten patients underwent investigation for sinus node dysfunction. Sinus cycle length shortened slightly, from 980 +/- 292 to 931 +/- 276 ms (p less than 0.01). Uncorrected or corrected sinus node recovery times or sinoatrial conduction time (according to the methods of Strauss and Narula) did not change in 6 patients with normal sinus node function and in 3 of 4 patients with abnormal sinus node function at rest. In the remaining patient maximal sinus node recovery time increased from a value at rest of 5,185 ms to 23,460 ms after flecainide. In the same patient sinoatrial conduction times at rest increased from 159 ms (Strauss method) and 143 ms (Narula method) to 1,398 and 1,455 ms, respectively, after flecainide. Thirty-three patients underwent electrophysiologic evaluation of anomalous atrioventricular (AV) pathways and reentrant tachycardias. Flecainide significantly prolonged accessory AV pathway anterograde and retrograde refractoriness. Anterograde accessory pathway block occurred in 33% of patients and retrograde accessory pathway block in 44%. Flecainide was successful in the acute termination of 86% of orthodromic atrioventricular reentrant tachycardias. In 15 patients with dual AV nodal pathways, only retrograde "fast" AH pathway refractoriness was significantly increased by flecainide, which was successful in the acute termination of 88% of intra-AV nodal reentrant tachycardias. In 28 patients who underwent endocardial pacing threshold assessment before and after i.v. flecainide, the acute threshold rose by a maximum of 117%, whereas the chronic threshold rose by a maximum of 83%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695817     DOI: 10.1016/0002-9149(84)90499-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Which patient should be referred to an electrophysiologist: supraventricular tachycardia.

Authors:  Richard J Schilling
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 2.  Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.

Authors:  Yadavendra S Rajawat; Darryl Dias; Edward P Gerstenfeld; Sanjay Dixit; Bindi Shah; Andrea M Russo; Francis E Marchlinski
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 3.  Flecainide: Current status and perspectives in arrhythmia management.

Authors:  George K Andrikopoulos; Sokratis Pastromas; Stylianos Tzeis
Journal:  World J Cardiol       Date:  2015-02-26

4.  Effects of flecainide on isolated vascular smooth muscles of rat.

Authors:  F Pérez-Vizcaino; J Duarte; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

5.  Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.

Authors:  A J Camm; K J Hellestrand; A W Nathan; R S Bexton
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 6.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

7.  Differing electrophysiological effects of class IA, IB and IC antiarrhythmic drugs on guinea-pig sinoatrial node.

Authors:  T Campbell
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

Review 8.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 9.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.

Authors:  Etienne Aliot; Alessandro Capucci; Harry J Crijns; Andreas Goette; Juan Tamargo
Journal:  Europace       Date:  2010-12-07       Impact factor: 5.214

10.  A case of acute ventricular capture threshold rise associated with flecainide acetate.

Authors:  Tae Soo Kang; Young Won Yoon; Sungha Park; Bum-Kee Hong; Dongsoo Kim; Hyuck Moon Kwon; Hyun-Seung Kim
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.